var data={"title":"Atomoxetine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Atomoxetine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5683?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=atomoxetine-drug-information\" class=\"drug drug_general\">see &quot;Atomoxetine: Drug information&quot;</a> and <a href=\"topic.htm?path=atomoxetine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Atomoxetine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708625\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Suicidal ideation in children and adolescents:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Atomoxetine increased the risk of suicidal ideation in short-term studies in children or adolescents with attention deficit hyperactivity disorder (ADHD). Anyone considering the use of atomoxetine in a child or adolescent must balance this risk with the clinical need. Comorbidities occurring with ADHD may be associated with an increase in the risk of suicidal ideation and/or behavior. Closely monitor patients who are started on therapy for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the prescribing health care provider. Atomoxetine is approved for ADHD in pediatric and adult patients. Atomoxetine is not approved for major depressive disorder (MDD).</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Pooled analyses of short-term (6- to 18-week), placebo-controlled trials of atomoxetine in children and adolescents (12 trials involving more than 2,200 patients, including 11 trials in ADHD and 1 trial in enuresis) have revealed a greater risk of suicidal ideation early during treatment in those receiving atomoxetine compared with placebo. The average risk of suicidal ideation in patients receiving atomoxetine was 0.4% compared with none in placebo-treated patients. No suicides occurred in these trials.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137799\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Strattera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855136\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Atomoxetine;</li>\n      <li>DOM-Atomoxetine;</li>\n      <li>Mylan-Atomoxetine;</li>\n      <li>PMS-Atomoxetine;</li>\n      <li>RIVA-Atomoxetine;</li>\n      <li>Sandoz-Atomoxetine;</li>\n      <li>Strattera;</li>\n      <li>Teva-Atomoxetine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051253\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Norepinephrine Reuptake Inhibitor, Selective</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051246\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=atomoxetine-drug-information\" class=\"drug drug_general\">see &quot;Atomoxetine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Attention-deficit/hyperactivity disorder:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children &ge;6 years and Adolescents, weighing &le;70 kg: Oral: Initial: 0.5 mg/kg/day; increase after a minimum of 3 days to ~1.2 mg/kg/day; may administer once daily in the morning or divide into 2 doses and administer in the morning and late afternoon/early evening; maximum daily dose: 1.4 mg/kg/<b>day</b> or 100 mg/<b>day</b>, whichever is less. <b>Note:</b> Doses &gt;1.2 mg/kg/day have not been shown to provide additional benefit. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dosage adjustment with concurrent strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine) use or patients known to be CYP2D6 poor metabolizers: Oral: Initial: 0.5 mg/kg/day for 4 weeks; increase dose to 1.2 mg/kg/day only if clinically needed and the initial dose is well tolerated; do not exceed 1.2 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children &ge;6 years and Adolescents, weighing &gt;70 kg and Adults: Oral: Initial: 40 mg daily; increase after a minimum of 3 days to ~80 mg daily; may administer once daily in the morning or divide into 2 doses and administer in morning and late afternoon/early evening. After an additional 2-4 weeks, may increase (if needed) to maximum daily dose: 100 mg/<b>day</b>. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dosage adjustment with concurrent strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine) use or patients known to be CYP2D6 poor metabolizers: Oral: Initial: 40 mg daily for 4 weeks; increase dose to 80 mg daily only if clinically needed and the initial dose is well tolerated; do not exceed 80 mg daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage adjustment in renal impairment:</b> Children &ge;6 years, Adolescents, and Adults:  No dosage adjustments are recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Children &ge;6 years, Adolescents, and Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderate hepatic impairment (Child-Pugh class B): Administer 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe hepatic impairment (Child-Pugh class C): Administer 25% of normal dose </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137779\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Strattera: 10 mg, 18 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Strattera: 25 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Strattera: 40 mg, 60 mg, 80 mg [contains corn starch, fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Strattera: 100 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137765\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874384\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089138.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlg6tq4JnhH0zep1hJdt9JxA==&amp;TOPIC_ID=13048\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089138.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051257\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to food. Do not crush, chew, or open capsule; swallow whole with water or other liquids. <b>Note:</b> Atomoxetine is an ocular irritant; if capsule is opened accidently and contents come into contact with eye, flush eye immediately with water and obtain medical advice; wash hands and any potentially contaminated surface as soon as possible. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137796\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051256\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages &ge;6 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002173\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">AtoMOXetine may be confused with atorvaSTATin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137822\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Some adverse reactions may be increased in &quot;poor metabolizers&quot; (CYP2D6).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cold extremities, flushing, increased diastolic blood pressure (&ge;15 mm Hg), orthostatic hypotension, palpitations, prolonged Q-T interval on ECG, syncope, systolic hypertension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, agitation, anxiety, chills, depression, disturbed sleep, dizziness, drowsiness, emotional lability, fatigue, headache (children and adolescents), hostility (children and adolescents), insomnia, irritability, jitteriness, paresthesia (adults; postmarketing observation in children), restlessness, sensation of cold</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Excoriation, hyperhidrosis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido, hot flash, increased thirst, menstrual disease, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, decreased appetite, dysgeusia, dyspepsia, flatulence, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysmenorrhea, dysuria, ejaculatory disorder, erectile dysfunction, orgasm abnormal, pollakiuria, prostatitis, testicular pain, urinary frequency, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Muscle spasm, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, conjunctivitis, mydriasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pharyngolaryngeal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Therapeutic response unexpected</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Alopecia, cerebrovascular accident, delusions, growth suppression (children), hallucination, hepatotoxicity, hypersensitivity reaction, hypomania, impulsivity, mania, myocardial infarction, panic attack, pelvic pain, priapism, Raynaud's phenomenon, rhabdomyolysis, seizure (including patients with no prior history or known risk factors for seizure), severe hepatic disease, suicidal ideation, tics</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137784\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to atomoxetine or any component of the formulation; use with or within 14 days of MAO inhibitors; narrow-angle glaucoma; current or past history of pheochromocytoma; severe cardiac or vascular disorders in which the condition would be expected to deteriorate with  clinically important  increases in blood pressure (eg, 15 to 20 mm Hg) or heart rate (eg,  20 beats/minute ).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Canadian labeling: Additional contraindications (not in U.S. labeling): Symptomatic cardiovascular diseases, moderate-to-severe hypertension; advanced arteriosclerosis; uncontrolled hyperthyroidism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137769\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aggressive behavior: New or worsening symptoms of hostility or aggressive behaviors have been associated with atomoxetine, particularly with the initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reactions: Anaphylactic reactions, angioneurotic edema, urticaria, and rash may occur (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Altered cardiac conduction: In clinical trials, at therapeutic doses, atomoxetine consistently did not prolong the QT/QTc interval; however, one placebo-controlled study in healthy CYP2D6 poor metabolizers demonstrated a statistically significant increase in QTc with increasing atomoxetine concentrations (Loghin 2012; Martinez-Raga 2013). Case reports suggest that atomoxetine overdose may increase the QT interval; however, this occurred when atomoxetine was combined with other agents known to have QT prolongation potential or inhibit CYP2D6 (Barker 2004; Sawant 2004). Atomoxetine, at high concentrations ex vivo, has demonstrated hERG channel block (Scherer 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular events: Atomoxetine has been associated with serious cardiovascular events including sudden death in patients with preexisting structural cardiac abnormalities or other serious heart problems (sudden death in children and adolescents; sudden death, stroke, and MI in adults). Atomoxetine should be avoided in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. Perform a prompt cardiac evaluation in patients who develop symptoms of exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during  treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Use may be associated with rare but severe hepatotoxicity, including hepatic failure; discontinue and do not restart if signs or symptoms of hepatotoxic reaction (eg, jaundice, pruritus, flu-like symptoms, dark urine, right upper quadrant tenderness) or laboratory evidence of liver injury are noted. The majority of reported cases occurred within 120 days of initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Orthostasis: Orthostasis and subsequent syncope may occur. Use with caution in patients predisposed to hypotension, or with conditions associated with abrupt heart rate or blood pressure changes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Priapism: Prolonged and painful erections (priapism), sometimes requiring surgical intervention, have been reported (rarely) with methylphenidate and atomoxetine use in pediatric and adult patients. Priapism has been reported to develop after some time on the drug, often subsequent to an increase in dose but also during a period of drug withdrawal (drug holidays or discontinuation). Patients with certain hematological dyscrasias (eg, sickle cell disease), malignancies, perineal trauma, or concomitant use of alcohol, illicit drugs, or other medications associated with priapism may be at increased risk. Patients who develop abnormally sustained or frequent and painful erections should discontinue therapy and seek immediate medical attention. An emergent urological consultation should be obtained in severe cases. Priapism has been associated with different dosage forms and products; it is not known if rechallenge with a different formulation will risk recurrence. Avoidance of stimulants and atomoxetine may be preferred in patients with severe cases that were slow to resolve and/or required detumescence (Eiland, 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psychiatric effects: Treatment-emergent psychotic or manic symptoms (eg, hallucinations, delusional thinking, mania) may occur in children and adolescents without a prior history of psychotic illness or mania.  Consider discontinuation of treatment if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; ADHD and comorbidities: Randomized, controlled trials have demonstrated that atomoxetine does not worsen anxiety in patients with existing anxiety disorders or tics related to Tourette&rsquo;s disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bipolar disorder: Use caution in patients with comorbid bipolar disorder; therapy may induce mixed/manic episodes. Atomoxetine is not approved for major depressive disorder; patients presenting with depressive symptoms should be screened for bipolar disorder. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustments necessary in moderate and severe hepatic insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertension: Use with caution in patients with hypertension and other cardiovascular or cerebrovascular conditions that might be exacerbated by increases in blood pressure or heart rate.  CYP2D6 poor metabolizers may experience greater increases in blood pressure and heart rate effects.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Urinary retention: Use with caution in patients with a history of urinary retention or bladder outlet obstruction; may cause urinary retention/hesitancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CYP2D6 poor metabolizers: Dosage adjustments are recommended in CYP2D6 poor metabolizers; these patients have increased exposure to atomoxetine. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: <b>[US. Boxed Warning]: Use with caution in pediatric patients; may be an increased risk of suicidal ideation.</b> Closely monitor for clinical worsening, suicidality, or unusual changes in behavior; especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. Growth should be monitored during treatment. Height and weight gain may be reduced during the first 9 to 12 months of treatment, but should recover by 3 years of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819840\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Serious cardiovascular events, including sudden death, may occur in patients with preexisting structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of atomoxetine in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the noradrenergic effects of atomoxetine. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as atomoxetine, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered. If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child. In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould 2009). In a large retrospective cohort study involving 1,200,438 children and young adults (aged 2 to 24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31 to 1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57 to 1.89) users compared to nonusers. It should be noted that due to the upper limit of the 95% CI, the study could not rule out a doubling of the risk, albeit low (Cooper 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\"> May cause significant increases in blood pressure and heart rate; in pediatric clinical trials, incidences of maximum increases in SBP, DBP, and HR compared to placebo were as follows: SBP (&ge;20 mm Hg): 12.5% vs 8.7%; DBP (&ge;15 mm Hg): 21.5% vs 14.1%; and HR (&ge;20 bpm): 23.4% vs 11.5%; monitor blood pressure and pulse at baseline, with dosage increases, and periodically during therapy. Use caution in patients with underlying medical conditions which may be exacerbated by increases in blood pressure and/or heart rate, including hypertension, tachycardia, or other cardiovascular or cerebrovascular conditions; use is contraindicated in patients with severe cardiovascular disorders who may experience clinical deterioration of condition with clinical increases in blood pressure or heart rate.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In pediatric patients, suppression of growth (height and weight) has been reported during the initial 9 to 12 months of therapy and has been shown to recover to normative values by 3 years of therapy; this growth pattern has been observed to be independent of pubertal status and patient&rsquo;s metabolic profile (ie, poor or extensive metabolizer); growth should be monitored during treatment. Evaluation of the effect of stimulants on growth in ADHD diagnosed children &lt;12 years receiving treatment for at least 3 years with stimulants has shown decreased height and weight changes over time compared to age matched control; height: 4.7 to 5.5 cm/year compared to 6.3 cm/year and 2.1 to 3.3 kg/year compared to 4.4 kg/year (Poulton 2016). In pediatric patients 8 to 17 years actively treated with stimulants, significant reductions in total femoral, femoral neck, and lumbar bone mineral density (BMD) were observed compared to matched unmedicated cohorts; also reported were significantly more subjects in the stimulant-treated group with BMD measurements in the osteopenic range compared to matched cohorts (38.3% to 21.6%) (Howard 2015). A longitudinal cohort-controlled trial reported no different in peak height velocity and final adult height in subjects with ADHD and/or treated with stimulants (Harstad 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137810\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (minor), CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137773\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13048&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: AtoMOXetine may enhance the tachycardic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May increase the serum concentration of AtoMOXetine. Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Selective Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the neurotoxic (central) effect of AtoMOXetine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: AtoMOXetine may enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137775\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137786\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Information related to atomoxetine use in pregnancy is limited; appropriate contraception is recommended for sexually active women of childbearing potential (Heiligenstein, 2003). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051252\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Family members and caregivers need to monitor patient daily for emergence of irritability, agitation, unusual changes in behavior, and suicide ideation. Pediatric patients should be monitored closely for suicidality, clinical worsening, or unusual changes in behavior, especially during the initial few months of therapy or at times of dose changes. Appearance of symptoms needs to be immediately reported to healthcare provider. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Evaluate for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor body weight, BMI, height and growth rate (in children); CNS activity; blood pressure and heart rate and rhythm (baseline, following dose increases, and periodically during treatment); liver enzymes in patients with symptoms of liver dysfunction; sleep, appetite, abnormal movements. Patients should be re-evaluated at appropriate intervals to assess continued need of the medication. Monitor for new psychotic symptoms, appearance or worsening of aggressive behavior, or hostility. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137768\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selectively inhibits the reuptake of norepinephrine (Ki 4.5 nM) with little to no activity at the other neuronal reuptake pumps or receptor sites.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137783\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>The pharmacokinetics in pediatric patients &ge;6 years of age have been shown to be similar to those of adult patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Up to 24 hours (Jain 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: IV: 0.85 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 98%, primarily albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, via CYP2D6 and CYP2C19; forms metabolites (4-hydroxyatomoxetine, active, equipotent to atomoxetine; N-desmethylatomoxetine, limited activity); <b>Note:</b> CYP2D6 poor metabolizers have atomoxetine AUCs that are ~10-fold higher and peak concentrations that are ~fivefold greater than extensive metabolizers; 4-hyroxyatomoxetine plasma concentrations are very low (extensive metabolizers: 1% of atomoxetine concentrations; poor metabolizers: 0.1% of atomoxetine concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 63% in extensive metabolizers; 94% in poor metabolizers</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Atomoxetine: 5 hours (up to 24 hours in poor metabolizers); Active metabolites: 4-hydroxyatomoxetine: 6-8 hours; N-desmethylatomoxetine: 6-8 hours (34-40 hours in poor metabolizers)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1-2 hours; delayed 3 hours by high-fat meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80%, as conjugated 4-hydroxy metabolite; &lt;3% is excreted unchanged); feces (17%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051261\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Atomoxetine hydrochloride is the R(-) isomer. Therapy may be discontinued without being tapered. Total daily doses &gt;150 mg/day and single doses &gt;120 mg/dose have not been systematically evaluated. Medications used to treat ADHD should be part of a total treatment program that may include other components such as psychological, educational, and social measures. If used for an extended period of time, long-term usefulness of atomoxetine should be periodically re-evaluated for the individual patient.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137785\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Atomoxetine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $427.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg (30): $427.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $427.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $463.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (30): $463.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $500.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $500.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Strattera Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $474.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg (30): $474.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $474.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $515.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (30): $515.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $556.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $556.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855137\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abretia (CL, CR, DO, GT, HN, NI, PA, PE, SV, UY);</li>\n      <li>Artlex (KR);</li>\n      <li>Attentho (CO);</li>\n      <li>Attentin (BD);</li>\n      <li>Attentrol (IN);</li>\n      <li>Axepta (IN);</li>\n      <li>Deaten (CL);</li>\n      <li>MIXRE (TW);</li>\n      <li>Passiva (PE);</li>\n      <li>Recit (AR);</li>\n      <li>Sophos (PY);</li>\n      <li>Strattera (AE, AR, AT, AU, BB, BE, BG, BH, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, IE, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, TH, TR, TW, UA, ZA);</li>\n      <li>Suev (BD);</li>\n      <li>Xenocy (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, &quot;ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,&quot; <i>Pediatrics</i>, 2011, 128(5):1007-22.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: http://americanheart.mediaroon.com/index.php?s=43&amp;item=422.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barker MJ, Benitez JG, Ternullo S, et al. Acute oxcarbazepine and atomoxetine overdose with quetiapine. <i>Vet Hum Toxicol</i>. 2004;46:130&ndash;132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/15171487/pubmed\" target=\"_blank\" id=\"15171487\">15171487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biderman J, Heiligenstein JH, Faries DE, at al, &ldquo;Efficacy of Atomoxetine Versus Placebo in School-Age Girls With Attention-Deficit/Hyperactivity Disorder,&rdquo; <i>Pediatrics</i>, 2002, 110(6), http://www.pediatrics.org/cgi/content/full/110/6/e75. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper WO, Habel LA, Sox CM, et al, &quot;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&quot; <i>N Engl J Med</i>, 2011, 365(20):1896-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/22043968/pubmed\" target=\"_blank\" id=\"22043968\">22043968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA and Pliszka SR, &quot;Attention-Deficit-Hyperactivity Disorder: An Update,&quot;  <i>Pharmacotherapy</i>, 2009, 29(6):656-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/19476419/pubmed\" target=\"_blank\" id=\"19476419\">19476419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould MS, Walsh BT, Munfakh JL, et al, &quot;Sudden Death and Use of Stimulant Medications in Youths,&quot; <i>Am J Psychiatry</i>, 2009, 166(9):992-1001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/19528194/pubmed\" target=\"_blank\" id=\"19528194\">19528194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. <i>Pediatrics</i>. 2014;134(4):e935-944.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/25180281 /pubmed\" target=\"_blank\" id=\"25180281 \">25180281 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heiligenstein J, Michelson D, Wernicke J, et al, &quot;Atomoxetine and Pregnancy; Author Reply,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2003, 42(8): 884-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howard JT, Walick KS, Rivera JC. Preliminary evidence of an association between ADHD medications and diminished bone health in children and adolescents.<i> J Pediatr Orthop</i>. 2015 Sep 20. [Epub ahead of print]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/26398435 /pubmed\" target=\"_blank\" id=\"26398435 \">26398435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kratochvil CJ, Heiligenstein JH, Dittmann R, et al, &ldquo;Atomoxetine and Methylphenidate Treatment in Children With ADHD: A Prospective, Randomized, Open-Label trial,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 2002, 41(7):776-84. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/12108801/pubmed\" target=\"_blank\" id=\"12108801\">12108801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loghin C, Haber H, Beasley CM, et al. Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. <i>Br J Clin Pharmacol</i>. 2013;75(2):538-549.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/22803597/pubmed\" target=\"_blank\" id=\"22803597\">22803597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivitiy disorder.<i> CNS Drugs</i>. 2013;27(1):15-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/23160939/pubmed\" target=\"_blank\" id=\"23160939\">23160939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Michelson D, Allen AJ, Busner J, et al, &ldquo;Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study,&rdquo; <i>Am J Psychiatry</i>, 2002, 159(11):1896-901. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/12411225/pubmed\" target=\"_blank\" id=\"12411225\">12411225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Michelson D, Faries D, Wernicke J, et al, &ldquo;Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Ramdomized, Placebo-Controlled, Dose-Response Study,&rdquo; <i>Pediatrics</i>, 2001, 108(5), http://www.pediatrics.org/cgi/content/full/108/5/e83. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/11694667 /pubmed\" target=\"_blank\" id=\"11694667 \">11694667 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newcorn JH, Michelson D, Kratochvil CJ, et al, &quot;Low-Dose Atomoxetine for Maintenance Treatment of Attention-Deficit/Hyperactivity Disorder,&quot; <i>Pediatrics</i>, 2006, 118(6):e1701-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/17101710/pubmed\" target=\"_blank\" id=\"17101710\">17101710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S and AACAP Work Group on Quality Issues, &quot;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2007, 46(7):894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. <i>Int Clin Psychopharmacol</i>. 2016;31(2):93-99. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/26544899 /pubmed\" target=\"_blank\" id=\"26544899 \">26544899 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose [letter]. <i>Am J Psychiatry</i>. 2004;161:757.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/15056530/pubmed\" target=\"_blank\" id=\"15056530\">15056530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scherer D, Hassel D, Bloehs R, et al. Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. <i>Br J Pharmacol</i>. 2009;156:226&ndash;236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/19154426/pubmed\" target=\"_blank\" id=\"19154426\">19154426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spencer T, Heiligenstein JH, Biederman J, et al, &ldquo;Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder,&rdquo; <i>J Clin Psychiatry</i>, 2002, 63(12):1140-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/12523874/pubmed\" target=\"_blank\" id=\"12523874\">12523874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson C, et al, &quot;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&quot; <i>Circulation</i>, 2008, 117(18):2407-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wernicke JF and Kratochvil CJ, &ldquo;Safety Profile of Atomoxetine in the Treatment of Children and Adolescents With ADHD,&rdquo; <i>J Clin Psychiatry</i>, 2002, 63(Suppl 12):50-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atomoxetine-pediatric-drug-information/abstract-text/ 12562062 /pubmed\" target=\"_blank\" id=\" 12562062 \"> 12562062 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13048 Version 125.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708625\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F137799\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F855136\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051253\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051246\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F137779\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F137765\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874384\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051257\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F137796\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051256\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8002173\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F137822\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F137784\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F137769\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819840\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F137810\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F137773\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F137775\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F137786\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051252\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F137768\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F137783\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1051261\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F137785\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F855137\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13048|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=atomoxetine-drug-information\" class=\"drug drug_general\">Atomoxetine: Drug information</a></li><li><a href=\"topic.htm?path=atomoxetine-patient-drug-information\" class=\"drug drug_patient\">Atomoxetine: Patient drug information</a></li></ul></div></div>","javascript":null}